P
SRPT icon

Pitcairn’s Sarepta Therapeutics SRPT Stock Holding History

Pitcairn’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,645
Closed -$260K – 753
2024
Q2 		$260K Buy
+1,645
New +$211K 0.02% 625
2023
Q4 		– Sell
-2,822
Closed -$342K – 695
2023
Q3 		$342K Buy
2,822
+21
+0.7% +$2.37K 0.03% 460
2023
Q2 		$321K Sell
2,801
-2,697
-49% -$348K 0.03% 491
2023
Q1 		$758K Sell
5,498
-719
-12% -$93.3K 0.07% 249
2022
Q4 		$806K Sell
6,217
-276
-4% -$32K 0.08% 219
2022
Q3 		$718K Sell
6,493
-847
-12% -$85.4K 0.08% 222
2022
Q2 		$550K Buy
7,340
+68
+0.9% +$5K 0.06% 276
2022
Q1 		$568K Buy
7,272
+1,047
+17% +$80.2K 0.05% 318
2021
Q4 		$561K Sell
6,225
-603
-9% -$51.5K 0.04% 339
2021
Q3 		$631K Sell
6,828
-947
-12% -$72.9K 0.04% 283
2021
Q2 		$604K Buy
7,775
+4,637
+148% +$352K 0.04% 285
2021
Q1 		$234K Buy
3,138
+1,151
+58% +$106K 0.02% 550
2020
Q4 		$339K Sell
1,987
-181
-8% -$26.8K 0.03% 401
2020
Q3 		$305K Sell
2,168
-291
-12% -$44.2K 0.03% 370
2020
Q2 		$394K Buy
2,459
+285
+13% +$38.8K 0.04% 278
2020
Q1 		$213K Sell
2,174
-642
-23% -$73.4K 0.03% 389
2019
Q4 		$363K Buy
+2,816
New +$284K 0.03% 334
2019
Q3 		– Sell
-1,885
Closed -$286K – 549
2019
Q2 		$286K Sell
1,885
-134
-7% -$16.3K 0.03% 409
2019
Q1 		$240K Buy
+2,019
New +$260K 0.03% 438

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Pitcairn's SRPT Position: Q3 2024 in Review

Pitcairn sold out of Sarepta Therapeutics (SRPT) in Q3 2024, closing a stake of 1,645 shares — an estimated $260K sold.

Pitcairn first reported a position in SRPT in Q1 2019 and held it in 19 quarters. The position peaked at $806K in Q4 2022. 457 funds tracked by Wall St. Rank hold SRPT as of Q3 2024.

  • Pitcairn reported no remaining Sarepta Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Pitcairn sold 1,645 Sarepta Therapeutics shares in Q3 2024, an estimated $260K.
  • Pitcairn first reported a position in Sarepta Therapeutics in Q1 2019 and held it in 19 quarters.
  • Pitcairn's Sarepta Therapeutics position peaked at $806K in Q4 2022.
  • 457 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2024.

Based on Pitcairn's 13F filing for Q3 2024, filed 12 Nov 2024.